Immunization

Neutralizing Antibodies Against DPT Induced by Recombinant BCG

Published in TB and Outbreaks Week, February 13th, 2001

- by Michelle Marble, staff medical writer -- Researchers in Brazil, seeking a new vaccine against diphtheria, pertussis, and tetanus (DPT), put a mutant twist on the old and reliable bacillus Calmette-Guerin (BCG) vaccine.

"BCG, the attenuated strain of Mycobacterium bovis, has been widely used as a vaccine against tuberculosis and is thus an important candidate as a live carrier for multiple antigens," wrote Eliane N. Miyaji and colleagues from the Instituto Butantan, Sao Paulo. "With the aim of developing a recombinant BCG (rBCG) vaccine against DPT, we analyzed the potential of CRM197, a mutated nontoxic derivative of diphtheria toxin, as the recombinant...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of TB and Outbreaks Week

Source: TB and Outbreaks Week (2001-02-13)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry